Juniper Pharmaceuticals, Inc. (JNP) Given Consensus Rating of “Buy” by Analysts
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has been assigned an average recommendation of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $23.00.
JNP has been the topic of several recent research reports. BMO Capital Markets upgraded Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $31.00 to $34.00 in a research note on Friday, July 14th. ValuEngine downgraded Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, HC Wainwright restated a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Monday, May 15th.
Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new stake in Juniper Pharmaceuticals during the 1st quarter valued at $100,000. KCG Holdings Inc. purchased a new stake in Juniper Pharmaceuticals during the 1st quarter valued at $112,000. TFS Capital LLC boosted its stake in Juniper Pharmaceuticals by 87.0% during the 1st quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after purchasing an additional 14,707 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Juniper Pharmaceuticals by 6.6% during the 1st quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 2,544 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Juniper Pharmaceuticals by 5,500.0% during the 2nd quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares during the last quarter. Institutional investors and hedge funds own 36.20% of the company’s stock.
Shares of Juniper Pharmaceuticals (NASDAQ JNP) traded down 2.22% on Wednesday, hitting $4.40. The company had a trading volume of 143,864 shares. The firm’s 50 day moving average price is $4.66 and its 200-day moving average price is $4.66. Juniper Pharmaceuticals has a 52 week low of $3.65 and a 52 week high of $6.40. The stock has a market capitalization of $47.71 million, a PE ratio of 5.68 and a beta of 0.22.
Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.10. The company had revenue of $13.96 million for the quarter, compared to the consensus estimate of $11.84 million. Juniper Pharmaceuticals had a return on equity of 21.49% and a net margin of 13.94%. Analysts forecast that Juniper Pharmaceuticals will post ($0.39) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/juniper-pharmaceuticals-inc-jnp-given-consensus-rating-of-buy-by-analysts.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.